
Anaphylactoid reaction to maltose 5% solution during spinal anaesthesia

Mikiko Enokibori MD,*
Makoto Kuge MD,*
Kenjiro Mori MD FRCA†

Purpose: A rare case of an anaphylactoid reaction to maltose solution is presented.

Clinical features: A 28-yr-old man underwent repair of bilateral inguinal hernia under spinal anaesthesia with dibucaine. At the end of operation, he developed generalized flush and circulatory collapse immediately after receiving Na acetate solution containing maltose, 5%, *iv*. The reactions were treated with 32 mg ephedrine and 250 mg methylprednisolone *iv*, and rapid infusion of 1,000 ml acetated Ringer's solution. The skin tests provoked positive responses to maltose solutions.

Conclusion: The clinical features and skin tests suggested that the episode was an anaphylactoid reaction to maltose. Maltose is one of the disaccharides (MW: 342) produced from starch and glycogen. Maltose solutions are used frequently in Japan as a carbohydrate source. Further study is required to confirm whether maltose has an immunological antigen-eliciting activity.

Objectif : Présenter une rare observation de réaction anaphylactoïde au maltose.

Éléments cliniques : Un homme de 28 ans a subi une cure bilatérale de hernie inguinale sous rachianesthésie à la dibucaïne. À la fin de l'intervention, il a présenté un érythème généralisé et un collapsus circulatoire après l'administration d'acétate de Na contenant du maltose à 5% *iv*. La réaction a été traitée avec 32 mg d'éphédrine et 250 mg de méthylprednisolone *iv* avec une perfusion rapide de 1 000 ml d'une solution de Ringer avec acétate. L'intradermoréaction était positive aux solutions de maltose.

Conclusion : Les éléments cliniques et les épreuves cutanées suggèrent une réaction anaphylactoïde au maltose. Le maltose est un dissaccharide (PM : 342) provenant de l'amidon et du glycogène. Au Japon, on administre souvent des solutions de maltose comme sources d'hydrates de carbone. Des épreuves supplémentaires sont nécessaires pour confirmer l'action antigénique du maltose.

From the Department of Anesthesiology,* Mitsubishi Kyoto Hospital and Department of Anesthesia,† Kyoto University Hospital.
Address correspondence to: Dr. Kenjiro Mori, Department of Anesthesia, Kyoto University Hospital, Sakyo-Ku, Kyoto, 606-01; Japan.
Phone: 81-75-751-3433; Fax: 81-75-752-3259; E-mail: kmori@kuhp.kyoto-u.ac.jp
Accepted for publication October 2, 1997.

A NAESTHETISTS may encounter acute life-threatening allergic reactions, i.e., anaphylaxis or anaphylactoid reactions, during anaesthesia. The incidence is increasing recently because of use of a greater number of drugs perioperatively.^{1,2} Allergic reactions to intravenous infusion are, however, rare. Maltose solution has been used widely in Japan as a carbohydrate source, which provides energy of twice the mass of sugar (and of calories) per millilitre as an equimolar solution of glucose.³ More than 15 million litres are estimated to be consumed each year, without serious adverse reactions. The present report is a case of anaphylactoid reaction to maltose solution.

Case report

A 28-yr-old man, weight 60 kg, height 172 cm, was scheduled for repair of bilateral inguinal hernias. Four months before the present admission, the patient was given 2 g cefotiam (antibiotics), and 250 ml lactated Ringer's solution with maltose 5% *iv*, for acute epididymitis. This infusion was followed by swelling and erythema over the face and legs, for which 250 mg methylprednisolone, and 20 mg glycyrrhizinate *iv*, were effective. No cardiovascular and respiratory changes were noted during this reaction. Intradermal testing of cefotiam before surgery was negative. Physical examination and laboratory tests revealed no abnormalities.

No preanaesthetic medication was given. Electrocardiographic leads, a blood pressure cuff, and a transcutaneous pulse oximeter were placed on arrival at the operating room and an intravenous infusion of acetated Ringer's solution was started. Blood pressure was 120/70 mmHg and heart rate 72 beats·min⁻¹. Dibucaine, 7.2 mg in 3 ml (of glucose 10%), was injected intrathecally at the L 3-4 interspace. Analgesia to pinprick reached T6 at five minutes. Blood pressure and heart rate were stable at 100/58 mmHg and 80 beats·min⁻¹. Midazolam, 5 mg, was administered *iv* for sedation. Ephedrine, 8 mg *iv*, was given to maintain blood pressure 15 min later. The patient was fully stable for one hour. After the operation was over at 1 hr 15 min, 0.3 mg flumazenil *iv* was administered and the patient regained consciousness. The Ringer's acetate solution, 1,000 ml, was followed by Na acetate solution containing maltose 5%. A few minutes later, blood pressure decreased precipitously to 70/36 mmHg and heart rate slowed to 40 beats·min⁻¹. Oxygen was administered via face mask, 400 ml maltose-containing solution was infused rapidly and a total of 32 mg ephedrine was given *iv*, but blood pressure further decreased to 46/20 mmHg. A gener-

alised erythematous rash was noted at that time, and anaphylaxis was suspected. Methylprednisolone, 500 mg, was administered *iv* and the maltose-containing solution was replaced with acetated Ringer's solution, 1,000 ml, which was infused rapidly. Blood pressure and heart rate returned close to the control level within 15 min. During this episode, the patient was conscious and did not complain of dyspnea. There was no audible wheezing, and SpO₂ remained at 99–100% with 1.0 of F_IO₂. Vital signs remained stable over the next 30 min. The erythema persisted for five hours and faded gradually.

The patient consented to skin tests with prick and intradermal injection to Na acetate solution with maltose 5%, lactated Ringer's solution with maltose 5%, maltose 10% solution, dextrose 10% solution, cefotiam, dibucaine, and flumazenil which were performed four weeks later by a dermatologist. Each solution was prepared with undiluted and tenfold serial dilution. Normal saline solution served as a negative and histamine solution (0.01 mg·ml⁻¹) as a positive control. In the prick tests, the patient demonstrated positive responses to maltose solutions: flare of 10 × 15 mm in diameter to 0.1 mg·ml⁻¹ maltose solution and 15 × 20 flare to 100 mg·ml⁻¹ maltose solution (the photographs were poor in quality and are not shown). Prick tests to the other agents were all negative. In the intradermal tests to serial diluted maltose solutions, the patient demonstrated negative responses to 0.1 and 1 mg·ml⁻¹ solutions, and positive responses to a 10 mg·ml⁻¹ solution; a wheal of 7 × 10 mm and flare of 17 × 20 mm in diameter (see Figure).

A whole-blood histamine-release test was performed. Results expressed as a percentage of total histamine are considered positive when >20% of total histamine has been released.⁴ In this case, maltose released 3.8, 4.2 and 4.1% of total histamine from whole blood in the presence of 10, 1 and 0.1 mg·ml⁻¹ maltose solutions, respectively.

Discussion

The patient demonstrated rapid development of generalised flush and hypotension after receiving Na acetate solution containing maltose 5% *iv*. He had suffered a similar though milder reaction to lactated Ringer's solution with maltose 5% on a previous occasion. The clinical features and history indicated that the episode was an anaphylactic or anaphylactoid reaction to *iv* maltose.

Skin testing is most frequently used for identifying the causative agent of allergic reactions.⁵⁻⁹ In the present case, even the most dilute concentration of




FIGURE Intradermal testing on the right arm of the patient. Arrow 1 represents a positive reaction to $10 \text{ mg}\cdot\text{ml}^{-1}$ maltose solution; arrows 2 and 3 negative reactions to 1 and $0.1 \text{ mg}\cdot\text{ml}^{-1}$ solution respectively; arrow 4 the positive control to histamine solution; and arrow 5 a negative one to normal saline solution.

maltose produced positive responses in the prick test, while only the highest concentration produced positive response in the intra-dermal test. It is generally agreed that the intradermal test gives positive, or more correctly false-positive response by a direct pharmacological histamine release. This was not the case in present study, and the intradermal tests gave negative results to the concentration that provoked positive response in the prick test. No explanation is available for these paradoxical findings. Although the prick test appears to be less sensitive, it seeks essentially antigenic recognition from sensitised lymphocytes,^{7,8,10} and the positive response in the prick test in the present patient confirmed maltose as the causative agent.

The histamine-release test was negative in the present study. The concentration of maltose used in the test, i.e., 10, 1 and $0.1 \text{ mg}\cdot\text{ml}^{-1}$, was based on an

assumption that the reaction begins to occur when approximately 50 ml maltose 5%, i.e., 2.5 g of maltose, is administered to a man of 60 kg. In most clinical studies, a close correlation has been noted between the results of skin tests and the histamine-release test.⁴ The failure of the present histamine-release test may possibly be referred to the difficulty to perform, and furthermore, to the possible presence of antibodies that compete for antigen and prevent it from reaching the IgE-sensitised basophils.⁴ The rate of false-negative has been reported 20%.⁴

Airway maintenance, oxygen administration, rapid intravenous infusion of crystalloid and/or colloid solutions of $>10 \text{ ml}\cdot\text{kg}^{-1}$, and epinephrine are the mainstay of treatment. The severity of symptoms reflects the quantity of mediators released.¹ Beta-adrenergic receptor stimulation increases the intracellular cyclic AMP of the basophils and mast cells, which phosphorylates the Ca^{2+} pump protein, and suppresses the mediator release. Intravenous epinephrine, initial dose $50\text{--}100 \text{ }\mu\text{g}$ in adults, $10 \text{ }\mu\text{g}\cdot\text{kg}^{-1}$ in children, should be given immediately. Repeated administration or infusion of epinephrine, $0.05\text{--}0.10 \text{ }\mu\text{g}\cdot\text{kg}^{-1}\cdot\text{min}^{-1}$, may also be required.^{2,11} Subcutaneous or intramuscular injection of $50 \text{ }\mu\text{g}\cdot\text{kg}^{-1}$ epinephrine, is an alternative to intravenous administration in less severe reactions¹ as arrhythmias occur. The arrhythmias are caused by an H_2 dysrhythmogenic effect of histamine on the atria and ventricles.² In the present case, at the initial stage of the reaction, we could not realize the occurrence of anaphylaxis or anaphylactoid reaction, and ephedrine was given in the usual dose for mild hypotension induced by spinal anaesthesia. Consequently, a considerable dose of ephedrine was required. Hypotension in this case was mild and rapid intravenous volume expansion with Ringer's acetate solution restored BP to the control level. Although corticosteroids are often administered for the treatment of allergic reaction, their theoretical value in acute phase is, at present, difficult to defend.

The patient had stable blood pressure without vasopressors under spinal anaesthesia to T6 for over one hour. However, the peripheral sympathetic block would prevent compensatory vasoconstriction and thus exaggerate the magnitude of hypotension as suggested by Stoelting.¹

Several reviews have appeared on the use of maltose infusions.^{3,13,14} It is a disaccharide and is found in cereal products and glucose syrups.¹² Intravenously administered maltose is transported into the cells partly independent of insulin, and then gradually hydrolysed to two glucose molecules.^{3,14} In Japan, maltose solution is commercially available and is used frequently, approximately >15 million litres per annum. The incidence of

adverse responses is extremely low, and only two cases have been reported.^{15,16} Both occurred following repeated administration, developed serious reactions, and skin tests indicated that maltose was responsible. No study has succeeded in identifying the antigenicity of maltose. Further investigation is required to confirm whether maltose has an immunological antigen-eliciting activity. Anaesthetists must always be alert to the possible occurrence of such allergic reactions even to the components of intravenous infusion.

- 15 *Ishii H, Shima T, Hoshi K, Iwatsuki N, Hashimoto Y.* A case of anaphylactoid reactions to lactated Ringer's solution with 5% maltose. (Japanese) *Masui* 1989; 38: 1217–21.
- 16 *Kimura M, Sunami K, Takeda A.* Two cases of anaphylactic shock induced by chlorhexidine gluconate and maltose. (Japanese) *Masui To Sosei* 1994; 30: 319–22.

References

- 1 *Stoelting RK.* Allergic reactions during anesthesia. *Anesth Analg* 1983; 62: 341–56.
- 2 *Withington DE.* Allergy, anaphylaxis and anaesthesia. *Can J Anaesth* 1994; 41: 1133–9.
- 3 *Weser E, Slesinger MH.* Metabolism of circulating disaccharides in man and the rat. *J Clin Invest* 1967; 46: 499–505.
- 4 *Siraganian RP, Hook WA.* Histamine release and assay methods for the study of human allergy. *In: Rose NR, Friedman H, Fahey JL (Eds.). Manual of Clinical Laboratory Immunology*, 3th ed. Washington, D.C. American Society for Microbiology 1986: 675–84.
- 5 *Kniker WT, Hales SW, Lee LK.* Diagnostic methods to demonstrate IgE antibodies: skin testing techniques. *Bull NY Acad Med* 1981; 57: 524–48.
- 6 *Fisher M.* Intradermal testing after anaphylactoid reaction to anaesthetic drugs: practical aspects of performance and interpretation. *Anaesth Intensive Care* 1984; 12: 115–20.
- 7 *Watkins J.* Investigation of allergic and hypersensitivity reactions to anaesthetic agents. *Br J Anaesth* 1987; 59: 104–11.
- 8 *Leynadier F, Sansarricq M, Didier JM, Dry J.* Prick tests in the diagnosis of anaphylaxis to general anaesthetics. *Br J Anaesth* 1987; 59: 683–9.
- 9 *Moneret-Vautrin DA, Laxenaire MC.* Skin tests in diagnosis of allergy to muscle relaxants and other anesthetic drugs. *Monogr Allergy* 1992; 30: 145–56.
- 10 *Watkins J.* Heuristic decision-making in diagnosis and management of adverse drug reactions in anaesthesia and surgery: the case of muscle relaxants. *Theor Surg* 1989; 4: 212–22.
- 11 *Bochner BS, Lichtenstein LM.* Anaphylaxis. *N Engl J Med* 1991; 324: 1785–90.
- 12 *Southgate DAT.* Digestion and metabolism of sugars. *Am J Clin Nutr* 1995; 62: 203S–11.
- 13 *Young SJM, Weser E.* The metabolism of circulating maltose in man. *J Clin Invest* 1971; 50: 986–91.
- 14 *Sprandel U, Heuckenkamp P-U, Zöllner N.* Utilization of intravenous maltose. *Nutr Metabol* 1975; 19: 96–102.